NanoViricides has shipped NV-387 oral gummies to the Democratic Republic of Congo (DRC) to prepare for patient enrollment in its Phase II clinical trial for Monkeypox treatment. The shipment enables the initiation of the study, which aims to evaluate the safety and effectiveness of the oral formulation against the hMPXV infection. Patient enrollment and dosing are expected to commence once staff training is completed in a few weeks.

Clinical trial site preparations are being conducted by Om Sai Clinical Research Pvt. Ltd., the company's contract research organization in India, along with associates in DRC. Despite travel restrictions, changing flight schedules, and cancellations, CRO personnel have visited the site multiple times to ensure readiness. The trial had previously faced delays due to a change in the clinical trial site away from Kinshasa, as the new location required substantial preparation to meet necessary standards.

An on-site examination by the CRO revealed that the new site needed significant upgrades. Additionally, preparations were hindered by travel restrictions within DRC and internationally, imposed following the May 17 declaration of a Public Health Emergency of International Concern (PHEIC) due to an Ebola outbreak in DRC. NanoViricides believes NV-387 could be a useful treatment for the current Ebola Bundibugyo Virus outbreak.

The company has received approval from the Regulatory Agency ACOREP of DRC to start the Phase II clinical trial. The study will focus on MPox Clade I, which is endemic in DRC and is considered more severe than MPox Clade II. NanoViricides has applied to the US FDA for Orphan Drug Designation for NV-387 for the treatment of MPox.

NV-387 is a broad-spectrum antiviral drug candidate designed to mimic human cells to trap and destroy viruses. The company believes this host-mimetic mechanism makes viral escape highly unlikely. NanoViricides is also developing NV-387 as a treatment for other viral infections, including RSV, COVID, and Influenza.

Key Developments

NanoViricides has filed a prospectus for a $50M mixed shelf offering, allowing the company to raise capital by issuing different securities over time. The filing was submitted to the U.S. Securities and Exchange Commission (SEC). This registration provides the company with the flexibility to access the public markets as needed without having to file separate paperwork for each offering.

Offering Details

The mixed shelf offering permits NanoViricides to issue a combination of securities, which may include common stock, preferred stock, debt securities, and warrants. The total amount registered under the prospectus is $50M. The company can utilize these funds for general corporate purposes, working capital, or strategic acquisitions.

Strategic Implications

By filing a shelf registration, NanoViricides positions itself to act quickly on financing opportunities. This approach reduces the time and cost associated with future securities offerings. The prospectus does not specify an immediate timeline for the sale of securities, indicating that the offerings will occur at the company's discretion based on market conditions and capital requirements.